Effect of RGD coupled MDA-7/IL-24 on apoptosis induction in a hepatocellular carcinoma cell line

Ebrahim Hosseini1, Seyed Younes Hosseini2, Tayebeh Hashempour3

  • 1Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran 1411713116, Iran.

Molecular Medicine Reports
|December 14, 2016
PubMed

Insights

Researchers modified the interleukin-24 (IL-24) gene to enhance its tumor-suppressing ability. The new SP.RGD.IL-24 construct showed improved tumor cell targeting and apoptosis induction in liver cancer cells, offering potential for gene therapy.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Gene Therapy

Background:

  • Interleukin-24 (IL-24), also known as melanoma differentiation-associated gene-7 (MDA-7), is a tumor suppressor gene.
  • IL-24 induces apoptosis in various cancer cells, with its efficacy linked to receptor binding.
  • Enhancing IL-24's antitumor effects is a key goal for cancer treatment strategies.

Purpose of the Study:

  • To engineer and evaluate a modified IL-24 construct with enhanced antitumor properties.
  • To assess the impact of replacing the intrinsic signal sequence of IL-24 with a SP.RGD4C sequence on its expression, secretion, and targeting.
  • To compare the efficacy of the modified SP.RGD.IL-24 with native IL-24 in inducing apoptosis in hepatocellular carcinoma cells.

Main Methods:

  • The SP.RGD.IL-24 and native IL-24 cDNA sequences were cloned into the pcDNA3.1 expression vector.
  • Enzyme-linked immunosorbent assay (ELISA) was used to compare expression and secretion levels.
  • HepG2 (cancerous) and LX-2 (normal) cells were transfected to evaluate targeting, apoptosis induction (Gadd153, Bax gene expression via RT-qPCR), and cell death (flow cytometry).

Main Results:

  • SP.RGD.IL-24 exhibited similar expression and secretion to native IL-24 but demonstrated significantly enhanced adherence to HepG2 tumor cells.
  • The modified construct led to a significant upregulation of pro-apoptotic genes (Gadd153 and Bax) in HepG2 cells compared to native IL-24.
  • Flow cytometry confirmed that SP.RGD.IL-24 induced a higher rate of apoptosis in HepG2 cells without affecting normal LX-2 cells.

Conclusions:

  • The novel RGD-coupled IL-24 construct (SP.RGD.IL-24) demonstrates potent anticancer activity, surpassing that of native IL-24.
  • This engineered cytokine shows enhanced tumor cell targeting and apoptosis induction, validating its potential in gene therapy.
  • The findings offer new perspectives for targeted cytokine therapy and its application in cancer treatment.

Related Concept Videos